Streetbeat News

KYTX

Kyverna Therapeutics Inc.

Industry

Research and Development in Biotechnology (except Nanobiotechnology)

Open

4.85

Mkt cap

188M

Volume

279K

High

4.85

P/E Ratio

-2.05

52-wk high

30.60

Low

4.32

Div yield

N/A

52-wk low

4.32

Kyverna Therapeutics announced key leadership changes, including Warner Biddle as CEO, and reported strong financials with $321.6 million in cash and equivalents. The company is advancing its KYSA clinical program and plans to present updated data at upcoming conferences.

Portfolio Pulse from

November 13, 2024 | 9:30 pm

UBS has initiated coverage on Kyverna Therapeutics with a Buy rating and set a price target of $13, indicating a positive outlook for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

October 10, 2024 | 1:34 pm

HC Wainwright & Co. has reiterated a Neutral rating for Kyverna Therapeutics (NASDAQ:KYTX) and maintained a $7 price target.

Portfolio Pulse from Benzinga Newsdesk

September 19, 2024 | 10:55 am

Kyverna Therapeutics presented promising patient data for KYV-101, a treatment for neuroinflammatory diseases, at the ECTRIMS 2024 symposium. The data highlights KYV-101's efficacy and safety in treating conditions like stiff-person syndrome, myasthenia gravis, and multiple sclerosis.

Portfolio Pulse from Benzinga Newsdesk

September 18, 2024 | 12:05 pm

Kyverna Therapeutics has appointed Warner Biddle as the new CEO, succeeding Peter Maag. Biddle brings over 30 years of experience in commercial and product planning, particularly in CAR T therapies. Additionally, Christi Shaw joins the Board of Directors, enhancing leadership in cell therapy development.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 12:02 pm

Toll Brothers reported strong earnings, leading to a 6.5% rise in its stock. Other companies like Keysight, Coty, and TJX also saw stock increases due to positive financial results or other favorable news.

Portfolio Pulse from Avi Kapoor

August 21, 2024 | 5:48 pm

HC Wainwright & Co. has maintained a Neutral rating on Kyverna Therapeutics (NASDAQ:KYTX) and lowered the price target from $8 to $7.

Portfolio Pulse from Benzinga Newsdesk

August 15, 2024 | 11:27 am

U.S. stock futures are trading higher this morning. Key stocks to watch include Home Depot, RumbleOn, Paysafe, Kyverna Therapeutics, and XP Inc. Home Depot is expected to report strong earnings, RumbleOn beat revenue estimates, Paysafe is anticipated to post solid earnings, Kyverna Therapeutics received FDA RMAT designation, and XP Inc. is expected to report earnings after the closing bell.

Portfolio Pulse from Avi Kapoor

August 13, 2024 | 7:44 am

Kyverna Therapeutics (NASDAQ:KYTX) reported a Q2 EPS of $(0.67), missing the analyst consensus estimate of $(0.64) by 4.69%.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:25 pm

Kyverna Therapeutics shares are trading higher after the company received U.S. FDA RMAT designation for KYV-101 in the treatment of progressive myasthenia gravis.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 8:25 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.